Mark Rubash Net Worth

The estimated Net Worth of Mark J Rubash is at least 2.73 百万$ dollars as of 3 May 2024. Mr. Rubash owns over 1,709 units of iRhythm Technologies Inc stock worth over 1,328,981$ and over the last 21 years he sold IRTC stock worth over 1,222,815$. In addition, he makes 179,987$ as Independent Director at iRhythm Technologies Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Rubash IRTC stock SEC Form 4 insiders trading

Mark has made over 51 trades of the iRhythm Technologies Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently he exercised 1,709 units of IRTC stock worth 505,727$ on 3 May 2024.

The largest trade he's ever made was exercising 69,000 units of iRhythm Technologies Inc stock on 26 April 2004 worth over 2,069,310$. On average, Mark trades about 5,960 units every 81 days since 2003. As of 3 May 2024 he still owns at least 17,760 units of iRhythm Technologies Inc stock.

You can see the complete history of Mr. Rubash stock trades at the bottom of the page.

Mark Rubash biography

Mark J. Rubash CPA serves as Independent Director of the Company. Most recently, from November 2016 to August 2018, Mr. Rubash served as a Strategic Advisor to Eventbrite, Inc., a privately-held e-commerce company, where he previously served as the Chief Financial Officer from June 2013 to November 2016. Prior to Eventbrite, Mr. Rubash was the Chief Financial Officer at HeartFlow, Inc., a privately-held medical device company, which he joined in March 2012, and at Shutterfly, Inc., a publicly-held e-commerce company, which he joined in November 2007. Mr. Rubash was also the Chief Financial Officer of Deem, Inc. (formerly, Rearden Commerce), a privately-held e-commerce company, from August 2007 to November 2007. From February 2007 to August 2007, Mr. Rubash was a Senior Vice President at Yahoo! Inc. and he held various senior finance positions at eBay Inc. from February 2001 to July 2005. Prior to that, Mr. Rubash was an audit partner at PricewaterhouseCoopers LLP, where he was most recently the Global Leader for their Internet Industry Practice and Managing Partner for their Silicon Valley Software Industry Practice. Mr. Rubash has served as a member of the board of directors and Chairman of the audit committee of Intuitive Surgical, Inc., a medical device company, since October 2007, as a member of the board of directors and Chairman of the audit committee of Line 6, Inc., a music technology company, from April 2007 to January 2014, as a member of the board of directors and audit committee of IronPlanet, Inc., a privately-held e-commerce platform for used heavy equipment, from March 2010 to May 2017, and as Chairman of the audit committee from October 2015 to May 2017. Mr. Rubash received his B.S. in Accounting from California State University, Sacramento.

What is the salary of Mark Rubash?

As the Independent Director of iRhythm Technologies Inc, the total compensation of Mark Rubash at iRhythm Technologies Inc is 179,987$. There are 10 executives at iRhythm Technologies Inc getting paid more, with Kevin King having the highest compensation of 4,774,140$.

How old is Mark Rubash?

Mark Rubash is 63, he's been the Independent Director of iRhythm Technologies Inc since 2016. There are 5 older and 17 younger executives at iRhythm Technologies Inc. The oldest executive at iRhythm Technologies Inc is Ralph Snyderman, 80, who is the Independent Director.

What's Mark Rubash's mailing address?

Mark's mailing address filed with the SEC is Kifer Road, Sunnyvale, Santa Clara County, California, 94086, United States.

Insiders trading at iRhythm Technologies Inc

Over the last 8 years, insiders at iRhythm Technologies Inc have traded over 124,847,276$ worth of iRhythm Technologies Inc stock and bought 150,000 units worth 2,550,000$ . The most active insiders traders include Holdings A/S Novo、Vijay K Lathi、Kevin M King. On average, iRhythm Technologies Inc executives and independent directors trade stock every 17 days with the average trade being worth of 1,872,546$. The most recent stock trade was executed by Brice Bobzien on 9 August 2024, trading 1,372 units of IRTC stock currently worth 96,506$.

What does iRhythm Technologies Inc do?

irhythm is a digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine- learning capabilities. our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ecg, monitoring for patients at risk for arrhythmias. we have created a unique platform, zio by irhythm, which we believe allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies, avoiding multiple indeterminate tests, allowing for appropriate medical intervention and potentially avoiding more serious downstream medical events, including stroke.

Complete history of Mr. Rubash stock trades at EBay、Intuitive Surgical Inc、iRhythm Technologies Inc、EBay

iRhythm Technologies Inc executives and stock owners

iRhythm Technologies Inc executives and other stock owners filed with the SEC include:

• Kevin King,
  President, Chief Executive Officer, Director
• David Vort,
  Executive Vice President - Sales
• Mark Day,
  Executive Vice President of Research and Development
• Kevin M. King,
  Consultant & Director
• Matthew C. Garrett,
  Advisor
• Daniel G. Wilson,
  Exec. VP of Strategy, Corp. Devel. & Investor Relations
• Douglas J. Devine,
  COO, CFO & Sec.
• David A. Vort,
  Exec. VP of Sales & Chief Commercial Officer
• Mark J. Day Ph.D.,
  Exec. VP of R&D
• Abhijit Talwalkar,
  Independent Chairman of the Board
• Mark Rubash,
  Independent Director
• Raymond Scott,
  Independent Director
• Bruce Bodaken,
  Independent Director
• Ralph Snyderman,
  Independent Director
• Cathleen Noel Merz,
  Independent Director
• Douglas Devine,
  Chief Financial Officer
• Renee Budig,
  Independent Director
• Mazi Kiani,
  Sr. VP of Quality & Regulatory
• Dietra N. Jones,
  Exec. VP of Clinical Operations
• Reyna M. Fernandez,
  Exec. VP & Chief HR Officer
• Dr. Mintu P. Turakhia M.D.,
  Chief Medical Officer & Chief Scientific Officer
• Allan B. Wilsker,
  Exec. VP of Information Technology & Customer Service
• Patrick Michael Murphy J.D.,
  Gen. Counsel
• Quentin S. Blackford,
  Pres & CEO
• Judith C. Lenane,
  Chief Clinical Officer & Exec. VP of Operations
• Kaja J. Odegard,
  VP of HR
• Marga Ortigas-Wedekind,
  Exec. VP of Marketing
• Michael J. Coyle,
  Pres, CEO & Director
• Tiba Aynechi,
  Director
• Life Science Partners L P S...,
  
• Venture Partners Xi, Lp Cro...,
  
• Matthew C. Garrett,
  Chief Financial Officer
• Life Science Partners L P S...,
  
• Holdings A/S Novo,
  10% owner
• Clercq Casper L. De,
  Director
• Michael J Coyle,
  President and CEO
• Vijay K Lathi,
  Director
• Karim Karti,
  Former Chief Operating Officer
• Derrick Sung,
  EVP, Strat Corp Development
• Mojdeh Poul,
  Director
• Brian B Yoor,
  Director
• Karen Ling,
  Director
• Mervin Smith,
  EVP Strategic Business Ops
• Marc W. Rosenbaum,
  Chief Accounting Officer
• Daniel G. Wilson,
  EVP, Corp Dev Inv Rel
• Brice Bobzien,
  Chief Financial Officer
• Quentin S. Blackford,
  President and CEO
• Minang Turakhia,
  EVP, CMO & CSO
• Reyna M Fernandez,
  EVP, Chief HR Officer
• Chad Patterson,
  Chief Commercial Officer
• Sumi Shrishrimal,
  EVP, Chief Risk Officer
• Patrick Michael Murphy,
  CBO and CLO